Ask AI
ProCE Banner Events

Share

Experts Discuss Advances in Newly Diagnosed Multiple Myeloma: The Impact of More Intensive Therapy on Clinical Outcomes

Join us live or virtually for an expert-led satellite symposium taking place in Madrid, Spain. This symposium will be held as part of the European Hematology Association 2024 Hybrid Congress and will focus on intensive therapy options for newly diagnosed multiple myeloma. Experts will discuss the latest evidence, highlight key clinical trials, address specific challenges and treatment strategies in newly diagnosed multiple myeloma, and answer audience questions. Please note: You must be registered for the EHA 2024 Congress to attend this symposium. You may register at: https://ehaweb.org/congress/eha2024-hybrid-congress/registration

Registration not open

Who Should Attend

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with newly diagnosed multiple myeloma.

Time and location

Thursday, June 13, 2024

7:00 PM - 8:45 PM Central European Summer Time (CEST)

In-person

7:15 PM - 8:45 PM Central European Summer Time (CEST)

Virtual

Ifema Madrid Recinto Ferial
Av. del Partenón, 5, Barajas, 28042
Madrid, Spain

Goya 1 Hall

Agenda

Thursday, 13 June 2024

19.15 - 20.45 CET

Registration and Refreshment 7:00 PM - 7:15 PM CET

Presentation: 7:15 PM - 8:45 PM CET

 

Agenda

  • Welcome and Introductions
  • The Evolving Rationale for Targeting CD38 in MM and Role in Pathophysiology
  • The Impact of Quadruplet Therapy Incorporating CD38 Antibodies in Transplant-Eligible Patients With NDMM
    • Panel discussion
  • Optimizing Clinical Outcomes With CD38 Antibodies for Transplant-Ineligible Patients With NDMM
    • Panel discussion
  • Specific Challenges With NDMM and Patient Subgroups, Including Risk- and Response-Adapted Treatment Strategies
    • Panel discussion
  • Audience Question and Answer Session

Location

Venue Name

Ifema Madrid Recinto Ferial

Address

Ifema Madrid Recinto Ferial
Av. del Partenón, 5, Barajas, 28042
Madrid, Spain

Room Name

Goya 1 Hall

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners to optimize CD38 antibody–based quadruplet regimens for patients with newly diagnosed multiple myeloma. 

Target Audience
This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with newly diagnosed multiple myeloma.

Learning Objectives.
Upon completion of this activity, participants should be able to:

    • Integrate CD38-targeted antibodies into treatment regimens for patients with newly diagnosed multiple myeloma to improve MRD and OS
    • Identify patients with newly diagnosed multiple myeloma who are most likely to benefit from anti-CD38 antibody–based quadruplet therapy regimens
    • Evaluate the efficacy and safety data for the available CD38-targeted agents, considering the unique features of each 
    • Improve awareness of racial and socioeconomic barriers to equitable access to high-quality myeloma care, including clinical trials

Accreditation

This educational activity is not certified for CME/CE credit.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Sanofi.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.